Drug Profile

Grass-pollen allergy immunotherapy sublingual - Lofarma

Alternative Names: LAIS^® Grass Tablets

Latest Information Update: 05 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lofarma S.p.A
Class Allergens; Antiallergics; Plant allergy immunotherapies
Mechanism of Action Immunosuppressants; T lymphocyte modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Allergic rhinoconjunctivitis

Most Recent Events

02 Jan 2023 Phase II development is still ongoing for Allergic rhinoconjunctivitis in Italy (Sublingual, Spray)
05 Dec 2020 Lofarma completes a phase II trial in Allergic rhinoconjunctivitis in Italy (EudraCT2018-004472-35)
12 Sep 2019 Lofarma initiates enrolment in a phase III trial for Allergic rhinoconjunctivitis in Italy (Sublingual) (EudraCT2019-001532-65)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com